Does Tango Therapeutics’ (TNGX) New ATM Plan Reframe Its Long‑Term Funding and Trial Risk Balance?
Tango Therapeutics recently announced a US$100 million at-the-market equity program and leadership changes ahead of its potentially pivotal 2026 vopimetostat combination study data. While these moves offer some funding flexibility and leadership depth, they underscore the company's reliance on this single program. Investors should be aware of the concentrated clinical risk and the wide range of fair value estimates, reflecting the stock's volatile nature and high-risk, high-valuation story.
10 Best Performing Stocks of Q1 2026 to Watch for Q2
This article highlights Tango Therapeutics, Inc. (NASDAQ:TNGX) as one of the best-performing stocks of Q1 2026, with a 134.27% performance. Major firms like Stifel and Jefferies have increased price targets and maintained Buy ratings due to progress in PRMT5 inhibitors and RAS(ON) combinations, and a supply agreement with ERAS. The company is a clinical-stage biotechnology firm focused on precision medicine for cancer treatment, with upcoming topline data expected for daraxonrasib.
10 Best Performing Stocks of Q1 2026 to Watch for Q2
This article highlights Tango Therapeutics, Inc. (NASDAQ:TNGX) as one of the top-performing stocks of Q1 2026, with a 134.27% performance. Analysts at Stifel and Jefferies have increased their price targets and maintained "Buy" ratings due to progress in its clinical programs for cancer treatment. Focusing on PRMT5 inhibitors and RAS(ON) combinations, the company is advancing its precision medicine efforts.
Canaccord Genuity initiates coverage of Tango Therapeutics (TNGX) with buy recommendation
Canaccord Genuity has initiated coverage of Tango Therapeutics (TNGX) with a "buy" rating. This indicates a positive outlook from the investment bank regarding the company's stock performance and future prospects.
Tango Therapeutics CFO sells $126,530 in TNGX stock
Tango Therapeutics CFO Daniella Beckman sold 10,317 shares of TNGX common stock for approximately $126,530. These sales were primarily to cover tax obligations related to restricted stock unit vesting. Despite the sales, Beckman also acquired significant restricted stock units and stock options, increasing her total direct ownership to 184,297 shares.
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 27,000 Shares of Stock
Adam Crystal, an insider at Tango Therapeutics (NASDAQ:TNGX), sold 27,000 shares of the company's stock on April 1st for $572,400 at an average price of $21.20, reducing his direct holdings by 19.34%. This sale is part of a larger trend of selling by Crystal, totaling over $2 million this year. Tango Therapeutics is currently trading near its 1-year high, and analysts maintain a "Moderate Buy" consensus with an average target price of $20.67, despite recent insider disposals.
Tango Therapeutics (NASDAQ: TNGX) president sells 27,000 shares
Crystal Adam, President of R&D at Tango Therapeutics (NASDAQ: TNGX), exercised stock options for 27,000 shares at an exercise price of $5.20 per share and subsequently sold all 27,000 shares at a weighted-average price of $21.2029. These transactions were executed on April 1, 2026, under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Adam directly holds 112,622 shares of Tango Therapeutics common stock.
Tango a new Buy at Canaccord Genuity on 2026 catalysts
Canaccord Genuity has initiated coverage on Tango with a Buy rating, citing several potential catalysts expected in 2026. These catalysts are anticipated to drive significant growth and value for the company.
Tango Therapeutics stock hits all-time high at 21.84 USD By Investing.com
Tango Therapeutics (TNGX) stock has reached an all-time high of $21.84, driven by significant investor interest and a 1449% surge over the past year. Despite this milestone and positive analyst price target adjustments, InvestingPro data suggests the stock may be overvalued and in overbought territory, with the company not expected to be profitable this year.
Tango Therapeutics stock hits all-time high at 21.84 USD By Investing.com
Tango Therapeutics (TNGX) stock has reached an all-time high of $21.84, trading at $21.78 with a market capitalization of $3.09 billion, reflecting a 1449% surge over the past year. Despite this, InvestingPro data suggests the stock might be overvalued and analysts indicate cautious optimism, with some raising price targets due to developments in their cancer treatment pipeline. The company reported a net loss of $38.7 million in Q4 2025.
Tango Therapeutics stock hits all-time high at 21.84 USD
Tango Therapeutics (TNGX) stock reached an all-time high of $21.84, driven by increasing investor confidence despite the company reporting a net loss in Q4 2025. While the stock has seen a significant surge of 1449% over the past year and analysts have raised price targets, InvestingPro data suggests it may be overvalued and in overbought territory, with profitability not expected this year.
Canaccord Genuity Group Begins Coverage on Tango Therapeutics (NASDAQ:TNGX)
Canaccord Genuity Group initiated coverage on Tango Therapeutics (NASDAQ:TNGX) with a "buy" rating and a $30 price target, suggesting a 41% upside. Other analysts have also raised their price targets, leading to a "Moderate Buy" consensus and an average target of $20.67. Despite recent insider selling, institutional investors hold a significant stake, and the company reported better-than-expected quarterly earnings.
Tudor Investment Corp ET AL Takes $450,000 Position in Tango Therapeutics, Inc. $TNGX
Tudor Investment Corp ET AL recently acquired a new position of 53,572 shares, valued at $450,000, in Tango Therapeutics, Inc. during the third quarter. While institutional investors hold a significant portion of the company's shares, there has been notable insider selling activity totaling approximately $1.97 million over the past 90 days. Despite insider sales, analysts maintain a largely bullish outlook on Tango Therapeutics, with a "Moderate Buy" consensus rating and an average price target of $19.50.
Tango Therapeutics is the best performing healthcare stock in March
This article states that Tango Therapeutics was the best-performing healthcare stock in March. No further details are provided in the content.
Tango Therapeutics is the best performing healthcare stock in March
The article states that Tango Therapeutics was the best-performing healthcare stock in March. Unfortunately, there is no further content to provide additional details or context regarding this performance.
TNGX - Tango Therapeutics Inc Stock Price and Quote
This page provides detailed stock information for Tango Therapeutics Inc (TNGX), including its market performance, financial metrics, recent analyst actions, and news headlines. It also lists insider transactions for several executives and the 10% owner, Third Rock Ventures IV, L.P., detailing their sales and proposed sales of company stock.
Adam Crystal Sells 12,000 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock
Adam Crystal, an insider at Tango Therapeutics (NASDAQ:TNGX), sold 12,000 shares of the company's stock on March 25th at an average price of $20.11, totaling $241,320. This transaction reduced his stake by 9.63% to 112,622 shares and follows several other significant sales in February and March. Analysts currently hold a "Moderate Buy" consensus rating for TNGX, with an average target price of $19.50.
Tango Therapeutics president sells $241k in shares
Adam Crystal, President, R&D at Tango Therapeutics, sold 12,000 shares of common stock worth approximately $241,320 on March 25, 2026, under a pre-arranged trading plan, and also exercised options. Following these transactions, Crystal directly owns 112,622 shares. Analysts from Stifel, Jefferies, and Mizuho have expressed optimism about Tango Therapeutics despite recent net losses, raising price targets and initiating positive coverage based on pipeline developments.
Tango Therapeutics (TNGX) R&D chief exercises options, sells 12,000 shares
Crystal Adam, President of R&D at Tango Therapeutics (TNGX), exercised stock options to acquire 12,000 shares at $5.20 each and subsequently sold all 12,000 shares in open-market transactions for a weighted-average price of $20.11 per share on March 25, 2026. These transactions were performed under a pre-arranged Rule 10b5-1 trading plan. Post-sale, Adam retains 112,622 shares of common stock and 460,500 stock options, indicating the sale was a relatively minor part of her overall holdings.
Tango Therapeutics (TNGX) price target increased by 32.09% to 20.06
This article reports a significant increase in Tango Therapeutics' (TNGX) price target. The target has been raised by 32.09% to $20.06. This indicates a positive outlook from analysts regarding the company's future stock performance.
Tango Therapeutics (NASDAQ: TNGX) — Vanguard reports 0 shares after realignment
The Vanguard Group has filed a Schedule 13G/A amendment for Tango Therapeutics (NASDAQ: TNGX), reporting 0 shares of Common Stock, representing 0% beneficial ownership. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing clarifies that this is a reporting shift and not an economic sale by Vanguard, with subsidiaries expected to disclose their holdings in future filings.
B. Riley Securities Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $21
B. Riley Securities has reiterated its Buy rating on Tango Therapeutics (TNGX.US) and increased its price target for the company's stock to $21. This adjustment reflects continued confidence in Tango Therapeutics' performance and future prospects.
TNGX: 93,000 shares from option exercise; Adam Crystal prior 10b5-1 sales (TNGX)
Tango Therapeutics (TNGX) has filed a Form 144 to sell 93,000 common shares resulting from a stock option exercise on March 25, 2026. The filing also details prior Rule 10b5-1 sales by Adam Crystal, including significant share disposals on March 5, February 25, and February 3, 2026, with their respective gross proceeds. This is considered a routine administrative filing providing transparency on insider transactions.
Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 9.3% - Still a Buy?
Tango Therapeutics (NASDAQ:TNGX) saw its stock price jump 9.3% to $21.30, with a market cap near $3.05 billion. While analysts have a "Moderate Buy" consensus rating and institutions significantly increased their holdings, the company remains unprofitable with recent insider selling.
Tango Therapeutics Ignites: 11% Surge to Historic Highs Signals Biotech Power Play
Tango Therapeutics (TNGX) experienced an 11% surge, hitting a new 52-week high of $21.82, driven by technical momentum and market sentiment rather than specific news. This outperformed the broader biotech sector, with leveraged ETFs like LABU also seeing significant gains. While the stock shows strong bullish signals, its high RSI suggests potential overextension, advising caution for investors.
Tango Therapeutics Ignites: 11% Surge to Historic Highs Signals Biotech Power Play
Tango Therapeutics (TNGX) experienced an 11% surge, reaching a new 52-week high of $21.82, driven by technical momentum and bullish market sentiment rather than specific news. This significant move outpaced other biotech leaders and is attributed to institutional accumulation, with strong technical indicators like an RSI of 89.4 and a positive MACD. The article suggests that while the stock is in an overbought state, tactical plays using leveraged ETFs and high-gamma calls could be considered, advising caution for direct stock purchases at current levels.
Tango Therapeutics stock hits all-time high at 19.83 USD By Investing.com
Tango Therapeutics (TNGX) stock has reached an all-time high of $19.83, reflecting a 1033.33% surge over the past year and a market capitalization of $2.8 billion. Despite this impressive performance, InvestingPro analysis suggests the stock is currently overvalued and in overbought territory according to its RSI. Analyst firms like Stifel, Jefferies, and Mizuho have shown optimism for Tango Therapeutics' future, raising price targets and initiating coverage with positive ratings based on developments in precision oncology programs.
Tango Therapeutics (TNGX) Valuation Scrutinized After Strong One Year Return And Elevated Price To Sales Multiple
Tango Therapeutics (TNGX) has seen a significant 1-year return of 10.16%, attracting investor attention despite reporting a net loss and generating US$62.384 million in revenue. The company's current price-to-sales (P/S) ratio of 44.4x is considerably higher than industry and peer averages, indicating a potentially overvalued market sentiment compared to its estimated fair P/S ratio of 2.4x. This high valuation, coupled with its early-stage clinical pipeline and ongoing losses, suggests that future setbacks could challenge current investor optimism.
Tango Therapeutics stock hits all-time high at 19.83 USD By Investing.com
Tango Therapeutics Inc. (TNGX) stock reached an all-time high of $19.83, marking a 1033.33% surge over the past year and achieving a $2.8 billion market capitalization. Despite this performance, InvestingPro data suggests the stock is overvalued with an overbought RSI. Analyst firms Stifel, Jefferies, and Mizuho have maintained or raised price targets, reflecting optimism about the company's precision oncology programs.
Tango Therapeutics (TNGX) Valuation Scrutinized After Strong One Year Return And Elevated Price To Sales Multiple
Tango Therapeutics (TNGX) has experienced a significant 1-year return of 10.16% and a 117.47% year-to-date return, despite reporting a net loss. The company's Price-to-Sales (P/S) multiple of 44.4x is considerably higher than industry and peer averages, indicating a potentially overvalued stock compared to its current revenue and early-stage pipeline. This high valuation, coupled with a net loss and an early clinical pipeline, suggests investors are very optimistic, but also that the stock carries significant risks.
Tango Therapeutics stock hits all-time high at 19.83 USD
Tango Therapeutics' stock has reached an all-time high of $19.83, marking a significant increase of over 1000% in the past year and a market capitalization of $2.8 billion. This surge reflects strong investor confidence in the company's biotechnology innovations, despite an InvestingPro analysis suggesting the stock is currently overvalued. The company recently reported a net loss for full-year 2025, but analysts from Stifel, Jefferies, and Mizuho have maintained or raised price targets, citing progress in its precision oncology programs.
Tango Therapeutics (TNGX) to Release Quarterly Earnings on Monday
Tango Therapeutics (TNGX) is set to release its Q4 2025 earnings before market open on Monday, March 30th, with analysts expecting an EPS of ($0.3182) and revenue of approximately $0.5 million. The stock recently traded near its one-year high, holding a "Moderate Buy" consensus from analysts with an average target price of $19.50. Insider selling has increased, though institutional investors hold a significant 78.99% of the company's stock.
Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates
Tango Therapeutics, Inc. (TNGX) reported better-than-expected earnings and revenues for the third quarter. The company posted a loss of $0.62 per share, which was narrower than the Zacks Consensus Estimate, and generated revenues of $2.44 million, significantly exceeding the forecast. This positive performance was primarily driven by strategic collaborations.
Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates
Tango Therapeutics, Inc. (TNGX) announced strong third-quarter results, surpassing both earnings per share and revenue estimates. The company reported a narrower-than-expected loss per share of $0.62, outperforming the Zacks Consensus Estimate of a $0.69 loss, and revenues of $7.86 million, significantly exceeding the $3.4 million estimate. This positive performance suggests the company is effectively managing its operations and development programs.
Wall Street Zen Downgrades Tango Therapeutics (NASDAQ:TNGX) to Sell
Wall Street Zen has downgraded Tango Therapeutics (NASDAQ:TNGX) from a "hold" to a "sell" rating, despite a wider analyst consensus of "Moderate Buy" with a $19.50 target price. The company has a $2.77 billion market cap and negative profitability, with analysts expecting a negative EPS for the current fiscal year. Recent insider sales included 133,884 shares, while institutional investors own nearly 79% of the stock.
Tango Therapeutics (TNGX) sees cautious analyst optimism following earnings
This article indicates that Tango Therapeutics (TNGX) is experiencing cautious optimism from analysts after its recent earnings report. The specific details of the earnings and the reasons for the cautious optimism are not provided in the snippet. To understand the full context, the complete article content would be necessary.
TNGX Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Tango Therapeutics Inc (TNGX). It synthesizes various technical indicators such as RSI, MACD, Moving Averages, and Support/Resistance levels to determine a "Strong Buy" consensus for the stock as of March 20, 2026. The analysis highlights that TNGX is trading above its key moving averages, although its RSI suggests it is in overbought territory.
Does Tango Therapeutics (TNGX) Trial Pact and ESOP Shelf Hint at a Pivotal Strategic Turn?
Tango Therapeutics reported a Q4 2025 net loss of US$38.75 million and a full-year 2025 net loss of US$101.59 million, with revenues of US$62.38 million. The company recently entered a clinical trial collaboration with Erasca to combine ERAS-0015 and vopimetostat for MTAP-deleted cancers, which is viewed as external validation of Tango's precision oncology approach. Despite this positive development and an extended cash runway, investors remain focused on financing and valuation risks due to a US$95.67 million ESOP-related shelf filing and a history of share dilution.
Tango Therapeutics stock hits 52-week high at $17.64
Tango Therapeutics (TNGX) stock has reached a new 52-week high of $17.64, reflecting a significant 787.18% growth over the past year. Despite being considered overvalued by InvestingPro, analysts maintain optimistic price targets, with some increasing their targets following advancements in the company's therapeutic programs and supply agreements. The company reported a net loss for Q4 2025 and the full year, but continues to advance its oncology pipeline.
Farallon Capital Management LLC Buys 1,600,000 Shares of Tango Therapeutics, Inc. $TNGX
Farallon Capital Management LLC increased its stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 17.5%, purchasing an additional 1,600,000 shares to bring its total ownership to 10,757,000 shares, valued at approximately $90.36 million. Despite insider sales totaling $1.72 million over the last quarter, the institutional investor now owns about 7.99% of the company. Tango Therapeutics, with a market cap of $2.47 billion, recently reported a quarterly EPS of -$0.29, beating estimates, and holds a consensus "Moderate Buy" rating from analysts with a $19.50 price target.
Tango Therapeutics, Inc. $TNGX Shares Sold by Trv Gp Iv LLC
Trv Gp Iv LLC significantly reduced its stake in Tango Therapeutics (TNGX) by 17.8%, selling almost 3 million shares, though the stock still represents a large portion of its portfolio. Despite insider selling totaling over $1.7 million, Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $19.50, following the company's recent beat on quarterly EPS expectations. Tango Therapeutics develops precision medicines targeting genetic vulnerabilities in cancer cells and recently announced positive earnings.
Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration
Tango Therapeutics (TNGX) stock has seen significant short-term gains following its Q4 and full-year 2025 results, an extended funding runway, and a new collaboration with Erasca. Despite these positive developments and strong share price performance, the company's valuation appears stretched with a P/S multiple of 39.6x, significantly higher than the industry average, while still being unprofitable. This indicates a potentially overvalued stock, suggesting investors are paying a high price for anticipated future growth.
Avoro Capital Advisors LLC Takes $4.58 Million Position in Tango Therapeutics, Inc. $TNGX
Avoro Capital Advisors LLC has acquired a new stake of 545,000 shares, valued at approximately $4.58 million, in Tango Therapeutics, Inc. This positions Avoro Capital Advisors LLC as owning about 0.40% of the company. Tango Therapeutics is a clinical-stage biotech company focused on precision cancer medicines, and despite recent insider stock sales, institutional investors collectively own a significant 78.99% of the shares.
Tango Therapeutics (TNGX) Soars 52% on Buy Reco
Tango Therapeutics (TNGX) stock surged 52% following a Buy recommendation from Cantor Fitzgerald. The firm cited the company's strong cash position, preclinical and clinical pipeline data, and potential for partnerships as key reasons for the upgrade. Cantor Fitzgerald has an overweight rating and a $30 price target on the stock.
Stifel raises Tango Therapeutics stock price target on PRMT5 data By Investing.com
Stifel increased its price target for Tango Therapeutics Inc. (NASDAQ:TNGX) to $24 from $15, reiterating a Buy rating. This adjustment follows promising data from PRMT5 inhibitor and RAS(ON) combinations, reducing risks for the company's first-line pancreatic ductal adenocarcinoma opportunity. Tango Therapeutics, which develops cancer therapies based on genetic drivers, has seen its stock rise significantly by 743% over the past year, currently trading near its 52-week high.
Insider sale: Tango Therapeutics (TNGX) R&D president sells shares
Crystal Adam, President of R&D at Tango Therapeutics (TNGX), sold 20,251 shares of common stock at $15.00 per share on March 5, 2026. This transaction was executed under a pre-established Rule 10b5-1 trading plan adopted in October 2025. Following the sale, Adam directly owns 112,622 shares of the company's common stock.
Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX)
Wedbush recently reaffirmed its Outperform rating for Tango Therapeutics (TNGX), increasing the price target from $15 to $19, indicating an upside of over 12%. This positive outlook follows the company's Q4 financial results and corporate updates, with particular note of their lead candidate, vopimetostat, which is expected to enter a pivotal study in 2026. Mizuho also initiated coverage with an Outperform rating and a $19 price target, anticipating significant outperformance with positive Phase I data in 2026 and potential risk-adjusted sales of $1.8 billion by 2035.
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
X4 Pharmaceuticals (XFOR), Immuneering (IMRX), and Tango Therapeutics (TNGX) have received renewed analyst attention with fresh or maintained Buy ratings. These small-cap biotechs are poised for significant clinical trial readouts in 2026, leading to substantial price targets from analysts, particularly for X4 Pharmaceuticals and Tango Therapeutics.
Adam Crystal Sells 20,251 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock
Adam Crystal, an insider at Tango Therapeutics (NASDAQ:TNGX), recently sold 20,251 shares of the company's stock for $303,765. This transaction is part of a series of sales totaling approximately 93,048 shares for $1.224 million across February and March, reducing his direct ownership to 112,622 shares. Despite this insider selling and a slight dip in TNGX's stock price, analysts maintain a largely positive outlook with an average "Moderate Buy" rating and a price target of $19.38.
Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX)
Wedbush has reaffirmed its Outperform rating for Tango Therapeutics (TNGX), increasing its price target from $15 to $19 after the company's Q4 financial results. Analysts noted that the company's lead candidate, vopimetostat, is on track for a pivotal study in 2026 for pancreatic cancer. Mizuho also initiated coverage with an Outperform rating, forecasting $1.8 billion in risk-adjusted worldwide sales for vopimetostat by 2035.
